Cerecor, a Baltimore pharmaceutical firm planning an preliminary public inventory providing, has launched a brand new medical research of an antidepressant it says will help sufferers who aren’t responding to plain remedies.
The corporate is conducting a randomized double-blind experiment to check a drug generally known as CERC-301 on 104 topics who’re experiencing extreme depressive episodes regardless of receiving different remedies. It’s a Part 2 medical trial, which suggests it’s in search of to show the drug triggers a organic response and has some effectiveness in comparison with a placebo.